Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours
Corran Roberts(Nuffield Orthopaedic Centre), Shibani Nicum(London Cancer), Victoria Y. Strauss(University of Oxford), Andrew R. Clamp, Lisa K. Folkes(Churchill Hospital), Sylwia Kopijasz(University of Oxford), Susana Banerjee(Royal Marsden NHS Foundation Trust), Richard D. Kennedy(Queen's University Belfast), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Michael R.L. Stratford(Regional Cancer Center), Charlie Gourley(Edinburgh Cancer Research), Jacinta Abraham(Velindre NHS Trust), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust)
Cited by 14
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k